Tiger Brokers

Mustang Bio FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million

Reuters
Mar 20
<a href="https://laohu8.com/S/MBIO">Mustang Bio</a> FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million
  • Mustang Bio published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.
  • Net loss narrowed to USD 1.92 million, while loss from operations was USD 2.43 million.
  • Research and development expense was a credit of USD 1.52 million, driven in part by USD 2.1 million of savings from settlements of aged payables, along with lower clinical-trial, outside-services, and license-related costs.
  • Cash and cash equivalents were USD 17.3 million and interest income was USD 511,000.
  • Mustang said it believes it has sufficient cash to fund operations for at least 12 months from the date of the filing, and it is exploring an investigator-sponsored, single-institution MB-109 trial at City of Hope that could be initiated in the second quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-032063), on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10